Sanofi-aventis announced that its subsidiary sanofi-aventis Mexico has acquired Laboratorios Kendrick (Kendrick) in a move to accelerate sales growth and further extend its pharmaceutical portfolio in emerging markets. Kendrick is a leading generic company in Mexico and one of the most dynamic in this market, with sales amounting to around 500 million Mexican pesos (around 26 million euros) in 2008. Kendrick's portfolio incorporates more than 50 active ingredients in the following therapeutic areas: analgesics, antihistamines, anti-infectives, antirheumatics, cardiovascular and central nervous system drugs.
Kendrick's market share in the Mexican generic market is estimated at 15 per cent (IMS MAT January 2009). Nicolas Cartier, general manager of sanofi-aventis Mexico said, "The Kendrick acquisition represents an exceptional opportunity to accelerate our growth in the generic market in Mexico. Sanofi-aventis proves once again its leadership and its commitment to offering quality medicines that satisfy the patient needs with one of the most comprehensive portfolios in the industry." Kendrick will enable sanofi-aventis to reinforce its leadership in Mexico and further extend the range of its pharmaceutical portfolio. This acquisition is one more step in the path to transform sanofi-aventis into a global healthcare leader.
Founded in 1946, Kendrick is one of the companies that actively participate within both the Private Market - pharmacies, chain outlets - and Government Tender market segments in Mexico.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment